HOME >> BIOLOGY >> NEWS
HPV testing a cost-effective strategy for women with equivocal cervical screening results

A new study has found that using human papillomavirus (HPV) DNA testing to determine who should receive a cervical examination called colposcopy is a cost-effective management strategy for women with equivocal Pap test results known as ASCUS (atypical squamous cells of undetermined significance). The study appears in the January 18 issue of the Journal of the National Cancer Institute.

About 5% of all Pap tests result in a diagnosis of ASCUS; however, only about 10% of women with this abnormality actually have precancer or cancer. The ASCUS and low-grade squamous intraepithelial lesions (LSIL) triage study (ALTS) was launched in the late 1990s to determine the best management strategy for women with these Pap test abnormalities that would both maximize the detection of clinically significant disease and reduce the need for unnecessary office visits and procedures. Results from ALTS, published in 2003, found that referring only those women with a positive HPV test to colposcopy was as effective at detecting cervical precancer or cancer as referring all women to colposcopy.

Shalini L. Kulasingam, Ph.D., of the Duke Center for Clinical Health Policy Research, and colleagues used data from 3488 women with ASCUS enrolled in ALTS to study the cost-effectiveness of three management strategies studied in ALTS--immediate colposcopy, HPV DNA testing, or conservative management with repeat Pap tests at 6-month intervals.

They found that the cost associated with HPV DNA testing was acceptable given the number of precancers and cancers found by this strategy. HPV DNA testing was less costly and detected more cases of precancer than immediately sending all women to receive colposcopy. The least costly strategy was a single repeat Pap test with referral to colposcopy for only those women with a high grade Pap test result; however, this option detected the fewest cases of precancer. The researchers conclude that HPV DNA testing for women with ASCUS
'"/>

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
17-Jan-2006


Page: 1 2

Related biology news :

1. Modular leukemia drug shows promise in early testing
2. Rapid syphilis testing in Haiti will prevent congenital disease and stillbirths
3. XDx to present recent success with AlloMap molecular expression testing
4. Potential genetic testing for substance abuse raises hope, concern
5. U-M team: Genetic testing sheds light on degenerative eye disease
6. Antiretroviral resistance testing in HIV infected patients improves health and saves costs
7. Professors to develop hand-held pathogen testing device
8. Animal testing alternative has ticks trembling at the knees
9. New research to cut animal testing
10. New method of testing eggs for abnormalities could solve problems of embryo freezing
11. HPV testing finds precancerous lesions at a higher rate than conventional pap smears

Post Your Comments:
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... July 30, 2015 after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
(Date:7/8/2015)... YORK , July 8, 2015  BD (Becton, ... BD & Guidepoint Mentor, a new program ... Guidepoint,s expert network services. BD is ... to improve healthcare delivery and outcomes and, with the ... entrepreneur will be able to directly engage with industry ...
(Date:7/7/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") a biometric ... revised version of one of its first 30 second commercials will ... New York , Chicago , ... metro areas.    , , , , ... the cards in your wallet and keep your identity secure. ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3
(Date:7/29/2015)... Inc. (NYSE: BIOA ) today announced that ... resigned.  The Company has hired Andrew Ashworth , ... 2014, as full time interim CFO and has launched ... Andy Ashworth began his employment today, to overlap ... was the Company,s CFO from September 2011 to December ...
(Date:7/29/2015)... July 29, 2015 ... the addition of the "Global Biosimilars Market, ... The Global Biosimilars Market, 2015 - ... rapidly growing biosimilars market. With the blockbuster biologics ... minimize costs, biosimilars are being viewed as viable ...
(Date:7/29/2015)... 2015  Pfenex Inc. (NYSE MKT: PFNX) announced today ... released on Thursday, August 13, 2015, before the open ... will host a conference call to discuss the financial ... outlining the financial results and business update will be ... call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... it has selected an optimized Erk inhibitor molecule ... the development of a new class of potential ... represents a prime target for therapeutic intervention in ... and survival benefits for B-Raf and Mek inhibitors. ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
Cached News: